Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just a thought

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Apr 21, 2021 9:54am

100 Views

Post# 33036256

RE:RE:RE:RE:RE:RE:RE:Just a thought

Fair enough, yeah your guess is probably correct.

In any event I only got my feet wet with this last spring, and this is the first bio stock I've bought into so I'm certainly learning a lot along the way. These boards have certainly helped me gain insight into what's a typical pathway for these companies. For most of my other investments there isn't the same kind of capital raises and licensing deals, so any speculating I am doing is just that.

I'm still long of course, I believe there is probably a lot of action happening behind the scenes that will only become apparent after the fact, just like the Nuance deal. We 've just got to ride it out!

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security